Developer docs
API playgroundTry for free, no card

Search company profiles

preCARDIA

Full company profile

uuid000z694

Namestring
preCARDIA
Websiteurl
precardia.com
Company typeenum
Private
Founded yearint
2017
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSaint Paul, United States
HQ citystring
Saint Paul
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
heart failure treatment, partially implantable device, acute decompensated heart failure, inpatient cardiac device, cardiac medical device
Industry2 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Medical Devices
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

preCARDIA develops and provides inpatient partially implantable medical devices designed to treat patients suffering from acute decompensated heart failure (ADHF). The device is used in hospital settings as a therapeutic intervention to manage fluid overload and cardiac decompensation in acutely ill heart failure patients.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1preCARDIA Inpatient Partially Implantable Heart Failure Device
CategoryCardiac Medical Devices
Description

A partially implantable medical device intended for inpatient use in treating patients with acute decompensated heart failure. Designed for hospital-based therapeutic intervention to manage acute cardiac decompensation.

No data
Peers10 records
TypeEmerging player
Description

Developer of the Revivent TC system for ventricular reshaping in heart failure patients — a structural heart device peer focused on remodeling therapies for failing ventricles.

2Abbott
TypeBroad incumbent
Description

Sells the HeartMate durable VAD and a broad cardiovascular portfolio, making it a key incumbent in the heart failure device space and a relevant strategic benchmark for preCARDIA.

TypeBroad incumbent
Description

A major cardiovascular medtech with heart failure and structural heart franchises; competes in adjacent device-based heart failure management and is a likely strategic acquirer of focused ADHF assets.

TypeBroad incumbent
Description

Acquired by Johnson & Johnson, Abiomed is a leader in temporary mechanical circulatory support (Impella) used in the inpatient heart failure and high-risk PCI setting — directly relevant to preCARDIA's inpatient ADHF device focus.

TypeBroad incumbent
Description

Global cardiovascular device leader with heart failure, cardiac surgery, and rhythm management franchises; relevant as both a competitive and potential strategic counterparty for heart failure device developers.

TypeEmerging player
Description

Develops the Aortix percutaneous circulatory support device for acute decompensated heart failure — a small, venture-backed peer pursuing a similar inpatient, catheter-delivered heart failure therapy.

TypeEmerging player
Description

Developer of the Carillon system, a catheter-based mitral annuloplasty device for functional mitral regurgitation in heart failure — a structurally similar catheter-delivered implant approach.

TypeEmerging player
Description

Developer of the Corvia Atrial Shunt, an implantable interatrial shunt device for heart failure with preserved ejection fraction — comparable as a small, venture-backed developer of catheter-delivered heart failure implants.

TypeEmerging player
Description

Developer of the AccuCinch system, a transcatheter ventricular restoration device for heart failure, with similar partially catheter-delivered implant positioning in the heart failure treatment paradigm.

TypeEmerging player
Description

Israel-based developer of an endovascular heart pump for high-risk PCI and cardiogenic shock, a close clinical and technological peer for catheter-based heart failure devices.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

preCARDIA

Cardiac Medical Devicesprecardia.com

preCARDIA firmographics

Firmographics
Name
preCARDIA
Website
https://precardia.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Ownership category
akta.pro rank

preCARDIA industry classification

Industry
Product category
Cardiac Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Heart failure treatment
  • Partially implantable device
  • Acute decompensated heart failure
  • Inpatient cardiac device
  • Cardiac medical device

Where preCARDIA is headquartered

Location

Headquarters

HQ city
Saint Paul
HQ country
United States
HQ region
North America

Markets served

preCARDIA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

preCARDIA product offering

Product offering

Core offering

preCARDIA develops and provides inpatient partially implantable medical devices designed to treat patients suffering from acute decompensated heart failure (ADHF). The device is used in hospital settings as a therapeutic intervention to manage fluid overload and cardiac decompensation in acutely ill heart failure patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • preCARDIA Inpatient Partially Implantable Heart Failure Device A partially implantable medical device intended for inpatient use in treating patients with acute decompensated heart failure. Designed for hospital-based therapeutic intervention to manage acute cardiac decompensation.

Companies that use preCARDIA

Customer profile

Ideal customer profiles1 record

preCARDIA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

preCARDIA competitors and assessment

Company assessment

Emerging players

  • BioVentrix: Developer of the Revivent TC system for ventricular reshaping in heart failure patients — a structural heart device peer focused on remodeling therapies for failing ventricles.
  • Procyrion: Develops the Aortix percutaneous circulatory support device for acute decompensated heart failure — a small, venture-backed peer pursuing a similar inpatient, catheter-delivered heart failure therapy.
  • Cardiac Dimensions: Developer of the Carillon system, a catheter-based mitral annuloplasty device for functional mitral regurgitation in heart failure — a structurally similar catheter-delivered implant approach.
  • Corvia Medical: Developer of the Corvia Atrial Shunt, an implantable interatrial shunt device for heart failure with preserved ejection fraction — comparable as a small, venture-backed developer of catheter-delivered heart failure implants.
  • Ancora Heart: Developer of the AccuCinch system, a transcatheter ventricular restoration device for heart failure, with similar partially catheter-delivered implant positioning in the heart failure treatment paradigm.
  • Magenta Medical: Israel-based developer of an endovascular heart pump for high-risk PCI and cardiogenic shock, a close clinical and technological peer for catheter-based heart failure devices.

Broad incumbents

  • Abbott: Sells the HeartMate durable VAD and a broad cardiovascular portfolio, making it a key incumbent in the heart failure device space and a relevant strategic benchmark for preCARDIA.
  • Edwards Lifesciences: A major cardiovascular medtech with heart failure and structural heart franchises; competes in adjacent device-based heart failure management and is a likely strategic acquirer of focused ADHF assets.
  • Abiomed: Acquired by Johnson & Johnson, Abiomed is a leader in temporary mechanical circulatory support (Impella) used in the inpatient heart failure and high-risk PCI setting — directly relevant to preCARDIA's inpatient ADHF device focus.
  • Medtronic: Global cardiovascular device leader with heart failure, cardiac surgery, and rhythm management franchises; relevant as both a competitive and potential strategic counterparty for heart failure device developers.

Market position

Customer concentration

preCARDIA social profiles

Digital presence

preCARDIA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

preCARDIA leadership team

Management profile

Number of profiles

preCARDIA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

preCARDIA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about preCARDIA

What does preCARDIA do?

preCARDIA develops and provides inpatient partially implantable medical devices designed to treat patients suffering from acute decompensated heart failure (ADHF). The device is used in hospital settings as a therapeutic intervention to manage fluid overload and cardiac decompensation in acutely ill heart failure patients.

When was preCARDIA founded?

preCARDIA was founded in 2017. It employs 1 to 10 people.

Where is preCARDIA based?

preCARDIA is headquartered in Saint Paul, United States, in the North America region.

Who are preCARDIA's main competitors?

Emerging players on record are BioVentrix, Procyrion, Cardiac Dimensions, Corvia Medical, Ancora Heart and Magenta Medical. Broad incumbents are Abbott, Edwards Lifesciences, Abiomed and Medtronic.

Does preCARDIA have an API?

No public API is recorded for preCARDIA.

What industry is preCARDIA in?

preCARDIA's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euSofinnova Partners closes oversubscribed €82M Sofinnova MD Start IV fundSofinnova Partners closed its fourth medtech fund, Sofinnova MD Start IV, at €82 million. The oversubscribed fund will support six to eight medtech companies over five years, following MD Start III's €63 million fund. The strategy aims to launch ventures from inception through clinical milestones.CardiacrhythmnewsAbiomed acquires breakthrough device company preCARDIAAbiomed has acquired preCARDIA, a developer of a catheter-based system designed to treat acute decompensated heart failure by reducing cardiac filling pressures. The acquisition integrates preCARDIA's technology into Abiomed's portfolio as the company prepares for future commercialization following its Breakthrough Device Designation from the FDA. PreCARDIA completed an early feasibility study showing technical success and safety in 30 patients.PharmiWeb.comAbiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure PatientsAbiomed has acquired preCARDIA, a medical device company developing a catheter-based system for treating acute decompensated heart failure. This acquisition integrates preCARDIA's proprietary technology into Abiomed’s portfolio to expand treatment options and potentially improve patient outcomes while lowering care costs. The preCARDIA system currently holds FDA Breakthrough Device Designation and is available only for investigational use.Mpo-magAbiomed Buys preCARDIA, a Heart Failure Tech FirmAbiomed has acquired preCARDIA, a developer of a catheter-based system designed to treat acute decompensated heart failure by reducing cardiac filling pressures. The acquisition adds preCARDIA's technology, which received FDA Breakthrough Device Designation and demonstrated safety in early feasibility studies, to Abiomed's existing portfolio. This move expands treatment options for patients with ADHF and aligns with Abiomed's strategy of innovation in heart failure care.PR NewswirepreCARDIA, Inc. Receives FDA Breakthrough Device Designation for Novel, Catheter Based Heart Failure TreatmentpreCARDIA, Inc. has received Breakthrough Device Designation from the FDA for its catheter-based system intended to treat acutely decompensated heart failure (ADHF) by reducing cardiac preload through superior vena cava occlusion. The designation grants the company priority review and engagement with FDA experts throughout the premarket review process, and qualifies the technology for an alternative new technology add-on payment pathway through CMS. The system is currently under investigation in the VENUS-HF Early Feasibility Study, with potential benefits including improved response to medical management, reduced rehospitalizations, and improved quality of life for the approximately 1.8 million patients hospitalized with ADHF annually in the United States.PR NewswirepreCARDIA Enrolls First Patient in Early Feasibility StudypreCARDIA, Inc. has enrolled the first patient in its VENUS-HF Early Feasibility Study at Tufts Medical Center in Boston, testing the preCARDIA system as a novel transcatheter treatment for acute decompensated heart failure. The study aims to gather critical safety and performance data for the device, which uses intermittent superior vena cava occlusion to address volume overload in patients who do not respond adequately to diuretics. The company states this enrollment milestone represents an important step toward providing a new therapeutic option for a condition affecting approximately 1.8 million patients annually in the United States, where treatment approaches have not improved over the past two decades.